The Advertising Standards Authority (ASA) in the UK has prohibited online pharmacies from promoting weight loss drugs to the public. This decision follows complaints regarding advertisements that were perceived to exploit viewers' insecurities about their weight, including a campaign aired during a commercial break of The Great British Bake Off. UK law prohibits the advertising of prescription-only medicines directly to consumers, as well as the promotion of drugs not authorized by health regulators. An investigation by the ASA revealed that some pharmacies were either violating these regulations or taking advantage of ambiguous areas to market weight loss injections and pills.
Eli Lilly, a pharmaceutical company, has faced backlash for a recent advertising campaign that suggested 'obesity is a disease.' While the campaign did not mention a specific drug, critics argued it still encouraged interest in prescription medications. In response, the ASA has issued new guidance regarding advertisements for weight loss treatments, emphasizing that advertising prescription-only medications, including weight loss injections like Wegovy and Mounjaro, is illegal in the UK.
Catherine Drewett, Investigations Manager at the ASA, stated that the new guidelines aim to clarify advertising standards for weight loss drugs. She noted the importance of preventing advertisements from encouraging unsafe treatment-seeking behavior. Recent rulings from the ASA included reprimands for Simple Online Pharmacy and Pharmacy Online for promoting oral weight loss drugs through social media and website content.
The ASA has also identified other pharmacies, including MedExpress and Juniper, that created advertisements leading consumers to infer the promotion of prescription-only weight loss medications. Experts believe that the ban on advertising prescription-only drugs is crucial for protecting public health and ensuring safe prescribing practices. The ASA previously allowed some mentions of weight loss injections on pharmacy websites, provided they were not prominently featured.
The Medicines and Healthcare products Regulatory Agency (MHRA) has commended the ASA for its swift action against misleading advertisements. Julian Breach, the MHRA's interim executive director of healthcare, reiterated the importance of compliance with advertising regulations to safeguard patient safety. He warned that violations could lead to significant regulatory actions, including fines and legal proceedings. However, there are concerns about whether these new regulations will effectively address the illegal sale and promotion of weight loss drugs, as over 2.5 million individuals in the UK are estimated to be using these medications, often at their own expense due to limited NHS access.